Select Subject

All (8717)

Agronomy (158)

Animal Husbandry,... (64)

Aquatic Science (16)

Astronomy (36)

Aviation (22)

Basic Medicine (184)

Biology (504)

Chemical Engineering (103)

Chemistry (635)

Civil and Archite... (105)

Clinical Medicine (236)

Computer Science ... (924)

Dynamic and Elect... (121)

Earth Science (119)

Economics (67)

Education (31)

Electrics, Commun... (927)

Energy Science an... (67)

Engineering and T... (15)

Environmental Sci... (140)

Food Science and ... (63)

Forestry (36)

Hydraulic Enginee... (40)

Mechanics (240)

Metallurgical Eng... (32)

Mine Engineering ... (38)

Nuclear Science a... (21)

Pharmacy (98)

Physics (920)

Preventive Medici... (37)

Psychology (20)

Security Science ... (17)

Sports Science (6)

Surveying and Map... (15)

Textile Science a... (16)

Traditional Chine... (56)

Transportation En... (57)

Select/Unselect all

For Selected Papers

Saved Papers

Please enter a name for this paper to be shown in your personalized Saved Papers list


	1. Teriparatide in the treatment of osteoradionecrosis of the jaws: a controlled clinical trial
	Hao Nie,Weihong Wang,Biao Xu,Jingyi Li,Yu Liu,Yemei Qian
	Clinical Medicine 14 February 2023
	Show/Hide Abstract \| Cite this paper︱Full-text: PDF (0 B)

	Abstract:Objective: To investigate the clinical therapeutic effect of teriparatide on osteoradionecrosis of the jaws (ORNJ). Materials and Methods: From May 2021 to November 2022, altogether 17 patients with ORNJ who consulted were divided into teriparatide and control groups. Following basic treatment including lesion removal, teriparatide group received subcutaneous administration of the drug (20ug/d) for two months, whereas control group received basic treatment only (including lesion excision.). Finally, patients underwent wound healing and jaw bone regeneration in the region of necrotic bone under observation. Results: There were seven patients in control group and ten in teriparatide group. In the course of treatment, two patients in teriparatide group withdrew from the research due to drug allergy and stroke, while the remaining eight experienced no side effects. A significant amount of new bone regeneration was observed in the region of dead bone in five patients in the teriparatide group, and their healing rate (37.5%) was higher than that of control group (14.2%) (P<0.001). Conclusion: Teriparatide can improve wound healing and new bone regeneration in patients with ORNJ after the removal of moribund bone from ORNJ.
	TO cite this article:Hao Nie,Weihong Wang,Biao Xu, et al. Teriparatide in the treatment of osteoradionecrosis of the jaws: a controlled clinical trial[OL].[14 February 2023] http://en.paper.edu.cn/en_releasepaper/content/4759022


	2. Key Differential Gene Analysis between Ewing Sarcoma Cado-Es1 Cell Line Tumor Stem Cells, Non-Tumor Stem Cells, and Mesenchymal Stem Cells
	Hongliang Wu,Sihang Zheng,Qun He,Yan Li
	Clinical Medicine 24 March 2022
	Show/Hide Abstract \| Cite this paper︱Full-text: PDF (0 B)

	Abstract:Background Ewing sarcoma is a highly malignant tumor. It is of great significance to identify new biomarkers or therapeutic targets. This study aimed to analyze the differentially expressed genes between Ewing sarcoma ERG type cell line cado-es1 tumor stem cell like cells, non-tumor stem cell like cells and mesenchymal stem cells (MSC) derived from Ewing sarcoma patients, and study the key genes related to Ewing sarcoma ERG type. Methods The NCBI SRA database data ERP104460 was retrieved, and three groups of MSC cells, tumor stem cell like cells (SP group) and non-tumor stem cell like cells (nsp group) obtained from different Ewing sarcoma patients were selected. The RNA-seq data of 9 samples in each group were analyzed to screen the significantly differentially expressed genes. Pathway enrichment analysis and the protein-protein interaction network was performed, and the hub genes were screened. Results Compared with MSC group, 8286 differentially expressed genes were obtained, including 3638 up-regulated genes and 4648 down-regulated genes. There were 9097 differentially expressed genes in nsp group compared with msc group, including 4800 up-regulated genes and 4297 down regulated genes. Compared with nsp group, four differentially expressed genes were obtained, including three up-regulated genes, U2, SNORA45b and RNU2-1. One down regulated gene was MTND1P27. These differentially expressed genes are mainly involved in biological processes and biological pathways such as cell division, cell cycle and DNA replication. By GO, KEGG and protein interaction network, 10 hub genes including THBS1, POSTN, COL1A1, COL1A2, MMP2, MMP14, SPARC, DCN, SPP1 and COL3A1 were screened in sp vs msc group; 10 hub genes including THBS1, MMP2, LOX, POSTN, COL1A1, COL1A2, MMP14, SPARC, DCN and SPP1 were obtained in nsp vs msc group. The key differential genes of PPI network between sp vs msc group and nsp vs msc group were COL3A1 and LOX. Conclusion THBS1, POSTN, COL1A1, COL1A2, MMP2, MMP14, SPARC, DCN, SPP1 and COL3A1 are key hub genes in Ewing sarcoma tumor stem cell like cells; THBS1, MMP2, LOX, POSTN, COL1A1, COL1A2, MMP14, SPARC, DCN and SPP1 are key hub genes in non-tumor stem cell like cells of Ewing sarcoma.
	TO cite this article:Hongliang Wu,Sihang Zheng,Qun He, et al. Key Differential Gene Analysis between Ewing Sarcoma Cado-Es1 Cell Line Tumor Stem Cells, Non-Tumor Stem Cells, and Mesenchymal Stem Cells[OL].[24 March 2022] http://en.paper.edu.cn/en_releasepaper/content/4757042


	3. Recent Advances of Circular RNA as a Potential Diagnostic and Therapeutic Target for Osteosarcoma
	Wu Hongliang,Zheng Sihang,Li Yan
	Clinical Medicine 23 March 2022
	Show/Hide Abstract \| Cite this paper︱Full-text: PDF (0 B)

	Abstract:Osteosarcoma is the most common primary malignant bone tumor, which is prone to early metastasis and poor prognosis. The current treatment methods need to be improved. Circular RNA is a covalently blocked circular endogenous non-coding RNA, which plays an essential role in the occurrence, development, clinical diagnosis, and treatment of various diseases. Understanding its role in osteosarcoma is conducive to the early detection, diagnosis, and treatment of osteosarcoma. In this paper, we reviewed the mechanism of action of circular RNA in the occurrence and development of osteosarcoma and its clinical application in recent years.
	TO cite this article:Wu Hongliang,Zheng Sihang,Li Yan. Recent Advances of Circular RNA as a Potential Diagnostic and Therapeutic Target for Osteosarcoma[OL].[23 March 2022] http://en.paper.edu.cn/en_releasepaper/content/4756972


	4. Measurement and correlation analysis of upper airway and mandible, hyoid in patients with bilateral anterior disc displacement
	Hou Yijun,Pan Xiaojing
	Clinical Medicine 23 March 2022
	Show/Hide Abstract \| Cite this paper︱Full-text:

Alert Name:
Alerting to:
Authentication email will be sent to your email address in 24 hours
Frequency:
Email Message Format:	Plain text Graphical(HTML)

Complete the form below and we will recommend the selected titles to your friends on your behalf. * Indicates a required field.
Your name*:
Your email address*:
Recipient's name*:
Recipient's email address*:
(multiple recipient's names and email addresses should be separated with semicolons)
Your comments:	I thought you would find the page(s) useful.

Your name:
Your email address:
Recipient's name:
Recipient's email address:
(multiple recipient's names and email addresses should be separated with semicolons)
Your comments:	I thought you would find this page useful.

Disclaimer: This message was sent to your friend using the "Send it to a friend" facility on the Sciencepaper Online’ WWW site, http://www.paper.edu.cn/en. The Sciencepaper Online is not responsible for the content of this email, and anything said in this email does not necessarily reflect the Sciencepaper Online's views.

	Check out RSS, or use RSS reader to subscribe this item